Wu, Yu Shen <br/><br/>
Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.  [electronic resource] 

 -  Oncotarget  Feb 2017 
 - 10703-10713 p.  digital 
<br/><br/> Publication Type: Journal Article; Meta-Analysis; Review; Systematic Review 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.12926  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab--adverse effects<br/>Chi-Square Distribution<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Odds Ratio<br/>Ovarian Neoplasms--drug therapy<br/>Randomized Controlled Trials as Topic<br/>Risk Factors<br/>Time Factors<br/>Treatment Outcome